145 related articles for article (PubMed ID: 32061159)
21. Clinical Management of Malignant Insulinoma: a single Institution's experience over three decades.
Yu J; Ping F; Zhang H; Li W; Yuan T; Fu Y; Feng K; Xia W; Xu L; Li Y
BMC Endocr Disord; 2018 Dec; 18(1):92. PubMed ID: 30522468
[TBL] [Abstract][Full Text] [Related]
22. Peptide receptor radionuclide therapy with
Magalhães D; Sampaio IL; Ferreira G; Bogalho P; Martins-Branco D; Santos R; Duarte H
J Endocrinol Invest; 2019 Mar; 42(3):249-260. PubMed ID: 29949120
[TBL] [Abstract][Full Text] [Related]
23. Malignant insulinoma misdiagnosed and treated as epilepsy.
Louda F; Chadli A; Elaziz S; Elghomari H; Farouqi A
Ann Endocrinol (Paris); 2013 Feb; 74(1):53-5. PubMed ID: 23351560
[TBL] [Abstract][Full Text] [Related]
24. Risk factors affecting prognosis in metachronous liver metastases from WHO classification G1 and G2 gastroenteropancreatic neuroendocrine tumors after initial R0 surgical resection.
Lv Y; Han X; Xu XF; Ji Y; Zhou YH; Sun HC; Zhou J; Fan J; Lou WH; Huang C
BMC Cancer; 2019 Apr; 19(1):335. PubMed ID: 30961559
[TBL] [Abstract][Full Text] [Related]
25. Prognostic validity of a novel American Joint Committee on Cancer Staging Classification for pancreatic neuroendocrine tumors.
Strosberg JR; Cheema A; Weber J; Han G; Coppola D; Kvols LK
J Clin Oncol; 2011 Aug; 29(22):3044-9. PubMed ID: 21709192
[TBL] [Abstract][Full Text] [Related]
26. Neuroendocrine tumors of the pancreas.
Varshney S; Johnson CD
Indian J Gastroenterol; 2000; 19(4):181-3. PubMed ID: 11059186
[TBL] [Abstract][Full Text] [Related]
27. Pancreatic neuroendocrine tumors.
Krampitz GW; Norton JA
Curr Probl Surg; 2013 Nov; 50(11):509-45. PubMed ID: 24206780
[No Abstract] [Full Text] [Related]
28. Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization.
Panzuto F; Nasoni S; Falconi M; Corleto VD; Capurso G; Cassetta S; Di Fonzo M; Tornatore V; Milione M; Angeletti S; Cattaruzza MS; Ziparo V; Bordi C; Pederzoli P; Delle Fave G
Endocr Relat Cancer; 2005 Dec; 12(4):1083-92. PubMed ID: 16322345
[TBL] [Abstract][Full Text] [Related]
29. Treatment of malignant pancreatic neuroendocrine neoplasms: middle-term (2-year) outcomes of a prospective observational multicentre study.
Zerbi A; Capitanio V; Boninsegna L; Delle Fave G; Pasquali C; Rindi G; Campana D; Falconi M;
HPB (Oxford); 2013 Dec; 15(12):935-43. PubMed ID: 23472667
[TBL] [Abstract][Full Text] [Related]
30. Management of a metastasized high grade insulinoma (G3) with refractory hypoglycemia: case report and review of the literature.
Scharf M; Mueller D; Koenig U; Pfestroff A; Nimphius W; Figiel J; Rinke A; Koenig A; Gress T
Pancreatology; 2014; 14(6):542-5. PubMed ID: 25459566
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of
Abou Jokh Casas E; Pubul Núñez V; Anido-Herranz U; Del Carmen Mallón Araujo M; Del Carmen Pombo Pasín M; Garrido Pumar M; Cabezas Agrícola JM; Cameselle-Teijeiro JM; Hilal A; Ruibal Morell Á
World J Gastroenterol; 2020 Apr; 26(13):1513-1524. PubMed ID: 32308351
[TBL] [Abstract][Full Text] [Related]
32. Insulinoma: a review of current management.
Bliss RD; Carter PB; Lennard TW
Surg Oncol; 1997; 6(1):49-59. PubMed ID: 9364660
[TBL] [Abstract][Full Text] [Related]
33. The functioning side of the pancreas: a review on insulinomas.
Maggio I; Mollica V; Brighi N; Lamberti G; Manuzzi L; Ricci AD; Campana D
J Endocrinol Invest; 2020 Feb; 43(2):139-148. PubMed ID: 31368049
[TBL] [Abstract][Full Text] [Related]
34. Increased EpCAM expression in malignant insulinoma: potential clinical implications.
Raffel A; Eisenberger CF; Cupisti K; Schott M; Baldus SE; Hoffmann I; Aydin F; Knoefel WT; Stoecklein NH
Eur J Endocrinol; 2010 Feb; 162(2):391-8. PubMed ID: 20097833
[TBL] [Abstract][Full Text] [Related]
35. Clinical characteristics, treatment and survival in patients with pancreatic tumors causing hormonal syndromes.
Grama D; Eriksson B; Mårtensson H; Cedermark B; Ahrén B; Kristoffersson A; Rastad J; Oberg K; Akerström G
World J Surg; 1992; 16(4):632-9. PubMed ID: 1357829
[TBL] [Abstract][Full Text] [Related]
36. A Nationwide Population-Based Study on the Survival of Patients with Pancreatic Neuroendocrine Tumors in The Netherlands.
Genc CG; Klümpen HJ; van Oijen MGH; van Eijck CHJ; Nieveen van Dijkum EJM
World J Surg; 2018 Feb; 42(2):490-497. PubMed ID: 29018912
[TBL] [Abstract][Full Text] [Related]
37. Gastroenteropancreatic grade 3 neuroendocrine tumors: a single entity or a heterogeneous group? A retrospective analysis.
Laffi A; Spada F; Bagnardi V; Frassoni S; Pisa E; Rubino M; Barberis M; Fazio N
J Endocrinol Invest; 2022 Feb; 45(2):317-325. PubMed ID: 34282554
[TBL] [Abstract][Full Text] [Related]
38. Insulinoma: A retrospective study analyzing the differences between benign and malignant tumors.
Câmara-de-Souza AB; Toyoshima MTK; Giannella ML; Freire DS; Camacho CP; Lourenço DM; Rocha MS; Bacchella T; Jureidini R; Machado MCC; Almeida MQ; Pereira MAA
Pancreatology; 2018 Apr; 18(3):298-303. PubMed ID: 29452754
[TBL] [Abstract][Full Text] [Related]
39. PROGNOSTIC FACTORS FOR SURVIVAL OF MEN1 PATIENTS WITH DUODENOPANCREATIC TUMORS METASTATIC TO THE LIVER: RESULTS FROM THE DMSG.
Conemans EB; Nell S; Pieterman CRC; de Herder WW; Dekkers OM; Hermus AR; van der Horst-Schrivers AN; Bisschop PH; Havekes B; Drent ML; Vriens MR; Valk GD
Endocr Pract; 2017 Jun; 23(6):641-648. PubMed ID: 28225311
[TBL] [Abstract][Full Text] [Related]
40. Surgical management of insulinomas: short- and long-term outcomes after enucleations and pancreatic resections.
Crippa S; Zerbi A; Boninsegna L; Capitanio V; Partelli S; Balzano G; Pederzoli P; Di Carlo V; Falconi M
Arch Surg; 2012 Mar; 147(3):261-6. PubMed ID: 22430908
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
